Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability and Food Effect of HDM1002 in Healthy Subjects
NCT06608329Phase 1Not yet recruiting
- Sponsor
- Huadong Medicine
- Start
- Oct 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of conveglipron in type 2 diabetes mellitus (T2DM) and obesity (3 cohorts), sponsored by Huadong Medicine. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Infinity, Area Under the Concentration-Time Curve From Time Zero to Time t and 6 more. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
conveglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06608329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06608329.